https://allsci.com/news/clinical-trials/lillys-jaypirca-on-course-to-reshape-post-btki-cll-treatment-after-beating-venetoclax/
Jaypirca Beats Venetoclax Alone in Relapsed CLL
Jun 15, 2026 - Eli Lilly's Jaypirca reduced disease progression risk by 45% vs venetoclax alone in relapsed CLL. Phase III data reshapes post-BTKi treatment options. Read...
jaypircabeatsvenetoclaxalonerelapsed
https://pharmacally.com/jaypirca-triple-combo-delays-relapse-in-phase-3-cll-trial/
Jaypirca Triple Combo Delays Relapse in Phase 3 CLL Trial - Pharmacally
Apr 13, 2026 - Phase 3 BRUIN CLL-322 shows that adding Jaypirca to venetoclax and rituximab significantly improves progression-free survival in relapsed CLL/SLL, with...
in phasejaypircatriplecombodelays